- Email: [email protected]
BETA-BLOCKERS, ANGIOTENSIN-CONVERTING ENZYME INHIBITORS OR ANGIOTENSIN RECEPTOR BLOCKERS, AND STATINS REDUCE MORTALITY IN PATIENTS WITH IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS
October 2008, Vol 134, No. 4_MeetingAbstracts Abstract: Poster Presentations | October 2008
BETA-BLOCKERS, ANGIOTENSINCONVERTING ENZYME INHIBITORS OR ANGIOTENSIN RECEPTOR BLOCKERS, AND STATINS REDUCE MORTALITY IN PATIENTS WITH IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS Hoang M. Lai, MD*; Wilbert S. Aronow, MD; Adam Kruger, MD; Harit Desai, MD; Harshad Amin, MD; William H. Frishman, MD; Martin Cohen, MD; Carmine Sorbera, MD New York Medical College, Valhalla, NY Chest Chest. 2008;134(4_MeetingAbstracts):p26001. doi:10.1378/chest.134.4_MeetingAbstracts.p26001
Abstract PURPOSE: The association of different cardiovascular drugs with mortality in patients with implantable cardioverter-defibrillators (ICDs) needed to be investigated. METHODS: In an academic cardiology practice, 965 patients who received an ICD . according to American College of Cardiology/American Heart Association guidelines were followed for mortality. The 965 patients included 778 men and 187 women, mean age 70±14 years. Followup was 32 ± 33 months. RESULTS: Death occurred in 208 of 965 patients (22%). Death occurred in 199 of 871 patients (23%) with a left ventricular ejection fraction (LVEF) <50% and in 9 of 94 patients (10%) with a normal LVEF (p<0.005). Death occurred in 73 of 515 patients (14%) treated with beta blockers,1 in 84 of 494 patients (17%) treated with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs),2 in 56 of 402 patients (14%) treated with statins,3 in 40 of 227 patients (18%) treated with amiodarone, 4 in 5 of 26 patients (19%) treated ewith sotalol, 5 and in 64 of 265 patients (24%) treated with no beta blocker, ACE inhibitor or ARB, statin, amiodarone, or sotalol6 (p<0.001 compaing 1 with 6 and 3 with 6; p<0.02 comparing 2 with 6). CONCLUSION: Patients with ICDs should be treated with beta blockers, ACE inhibitors or ARBs, and statins to reduce mortality. CLINICAL IMPLICATIONS: Patients with ICDs should be treated with beta blockers, ACE inhibitors or ARBs, and statins to reduce mortality.
DISCLOSURE: Hoang Lai, No Financial Disclosure Information; No Product/Research Disclosure Information Tuesday, October 28, 2008 1:00 PM - 2:15 PM
BETA-BLOCKERS, ANGIOTENSINCONVERTING ENZYME INHIBITORS OR ANGIOTENSIN RECEPTOR BLOCKERS, AND STATINS REDUCE MORTALITY IN PATIENTS WITH IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS Hoang M. Lai, MD*; Wilbert S. Aronow, MD; Adam Kruger, MD; Harit Desai, MD; Harshad Amin, MD; William H. Frishman, MD; Martin Cohen, MD; Carmine Sorbera, MD New York Medical College, Valhalla, NY Chest Chest. 2008;134(4_MeetingAbstracts):p26001. doi:10.1378/chest.134.4_MeetingAbstracts.p26001
Abstract PURPOSE: The association of different cardiovascular drugs with mortality in patients with implantable cardioverter-defibrillators (ICDs) needed to be investigated. METHODS: In an academic cardiology practice, 965 patients who received an ICD . according to American College of Cardiology/American Heart Association guidelines were followed for mortality. The 965 patients included 778 men and 187 women, mean age 70±14 years. Followup was 32 ± 33 months. RESULTS: Death occurred in 208 of 965 patients (22%). Death occurred in 199 of 871 patients (23%) with a left ventricular ejection fraction (LVEF) <50% and in 9 of 94 patients (10%) with a normal LVEF (p<0.005). Death occurred in 73 of 515 patients (14%) treated with beta blockers,1 in 84 of 494 patients (17%) treated with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs),2 in 56 of 402 patients (14%) treated with statins,3 in 40 of 227 patients (18%) treated with amiodarone, 4 in 5 of 26 patients (19%) treated ewith sotalol, 5 and in 64 of 265 patients (24%) treated with no beta blocker, ACE inhibitor or ARB, statin, amiodarone, or sotalol6 (p<0.001 compaing 1 with 6 and 3 with 6; p<0.02 comparing 2 with 6). CONCLUSION: Patients with ICDs should be treated with beta blockers, ACE inhibitors or ARBs, and statins to reduce mortality. CLINICAL IMPLICATIONS: Patients with ICDs should be treated with beta blockers, ACE inhibitors or ARBs, and statins to reduce mortality.
DISCLOSURE: Hoang Lai, No Financial Disclosure Information; No Product/Research Disclosure Information Tuesday, October 28, 2008 1:00 PM - 2:15 PM